AzTrials
AzTrials

NAFLDNAFLDNCT02358928

Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome

A study testing Diet Intervention in people with NAFLD and Fatty Liver, run by University of Texas Southwestern Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Concurrent with the rising prevalence of childhood obesity, the co-morbid condition of non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease among children. Read more about this study

Who is it for?
Ages 11 to 17 years
Conditions the study is for
NAFLD, Fatty Liver, Obesity
What is being tested?
Diet Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteUnited States
Study dates
Jul 2014to 18 Aug 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 11 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age 11 - 17 years
  • Male and Female subjects
  • BMI >= 95th percentile according to CDC body mass index chart for age and gender
  • Must be willing to participate and undergo "willingness to change" evaluation
  • Metabolic Syndrome(MetS) which is defined when 3 of the following are met:
  • Central adiposity (waist circumference ≥90th% for age and sex)
Show all 11Show fewer
  • Hypertriglyceridemia (triglycerides ≥ 110mg/dl)
  • Low HDL cholesterol ≤40mg/dl
  • Elevated blood pressure systolic or diastolic blood pressure > 90th % adjusted for age, sex and height or ≥ 130/85
  • IFG (Impaired fasting glucose ≥ 100mg/dl or elevated HOMA- IR ≥3.16)
  • ALT greater than 60 U/L and Non Alcoholic Fatty Liver Disease based on histologic confirmation on liver biopsy (minimum of 5% of hepatocytes with macrovesicular fat) obtained within 6 months before randomization

Who cannot join

  • Those patients with a history of poor compliance or adherence to energy restriction diets
  • Patients on medications that could alter appetite including glucocorticoids, psychostimulants (Vyvanse, Adderall), psychotropic medications (Zoloft, Risperdal), and antihyperglycemic medications (metformin, sulfonylurea)
  • Patients with the following illnesses:
  • Type 2 diabetes
  • Renal disease
  • Mental diseases (mood, psychotic and anxiety disorders)
Show all 15Show fewer
  • Developmental delay
  • Autism and autism spectrum disorders
  • Any liver disease except for non alcoholic fatty liver (NAFLD)
  • Metabolic disorders (tyrosinemia, glycogen storage disease, lysosomal disorders)
  • Congenital heart disease
  • Myopathies or muscular disorders/disability
  • Patients who follow a (cultural or religious) vegetarian lifestyle as this would not be compatible with Carbohydrate Restriction (need for high quality protein)
  • Prepubertal patients defined by a tanner stage of 1
  • Current or history of significant alcohol consumption

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UTexasSouthwestern/Childrens Medical Center

    Dallas, Texas, 75234

Other trials in United States

About this study

Concurrent with the rising prevalence of childhood obesity, the co-morbid condition of non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease among children. NAFLD is characterized by accrual of excess triglycerides (TG) in the liver that leads to inflammation, fibrosis, and cirrhosis. One-third of the pediatric population has NAFLD, a disease strongly associated with insulin-resistance and metabolic-syndrome (Met-S). NAFLD is predicted to become the leading cause of liver transplantation in adults by 2030.

Current understanding of NAFLD indicates that presence of excess TG in liver is an absolute requirement for disease progression. First-line therapy for NAFLD is focused on decreasing adiposity and improving insulin sensitivity through diet and exercise. Recent adult data indicate that dietary carbohydrate-restriction is more effective at reducing hepatic TG-content than traditional calorie-restriction. Few studies have been conducted to establish resolution of hepatic steatosis by any intervention. Such studies in pediatrics are primarily limited by a need for liver biopsy. However, hepatic proton magnetic resonance spectroscopy (H-MRS) is a new innovative tool used to quantitatively measure hepatic TG content in a non-invasive manner.

Read more

The primary aim is to compare the impact of dietary weight loss via carbohydrate-restriction and calorie-restriction on hepatic TG-content quantified by H-MRS in obese children with biopsy-proven NAFLD and Met-S.

This IRB approved protocol is a randomized control study. The investigators will recruit subjects from the Center for Obesity and its Consequences in Health and the pediatric gastroenterology clinics between the ages of 11-17 years who meet criteria for NAFLD and Met-S. A H-MRS will be obtained in each subject prior to the start of dietary intervention. Fifty-four subjects will be randomized to either a carbohydrate-restricted or calorie-restricted diet for 6 months with no change in baseline activity. A repeat H-MRS will be compared to baseline to determine the whether dietary carbohydrate-restriction is superior to calorie-restriction for reducing hepatic TG content. The investigators believe that subjects on the carbohydrate-restricted diet will have marked decrease in hepatic TG content compared to those in the calorie-restricted diet given the same degree of reduction in body mass index.

Read the detailed description

Specific Aims and Hypothesis:

The Primary aim is:

To compare the impact of dietary weight loss via carbohydrate-restriction and calorie-restriction on hepatic TG content quantified by H-MRS in obese children with biopsy-proven NAFLD and Met-S.

Our Secondary aims are:

To compare BMI z-score, ALT (analine transaminase) and cytokeratin 18 in obese patients with NAFLD and Met-S after a 6 month dietary weight loss via either carbohydrate or calorie restriction.

Hypothesis: Obese children with biopsy-proven NAFLD and Met-S will experience a reduction in liver TG content, assessed by H-MRS, concurrent with 6 months of dietary weight loss; however, we anticipate that subjects undergoing carbohydrate restriction will experience a greater reduction in hepatic fat than those undergoing calorie restriction due to the limiting of precursors for lipid synthesis inherent to the diet (CHO) and the expected increase in hepatic oxidative metabolism (TG accrual is attenuated while disposal is enhanced).

Methodology:

Design:

Our study is a 6 month prospective randomized controlled trial with outcomes assessment monthly for the first 6 months and a follow up visit at 10- 12 months after randomization.

Setting:

Recruitment and data collection will be completed at University of Texas Southwestern Medical Center and Children's Health, Dallas TX by study personnel. All patients who agree to participate will give informed written consent and assent. A study staff member will explain the study and review the consent and HIPAA forms with each patient. A copy of each signed form will be kept in the patient's study file. Each patient will also receive signed copies.

Subjects:

All patients referred (male and female) within the age range of 11 - 17 years who are obese (BMI >= 95th percentile) and meet criteria for metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) will be offered to participate in study.

Inclusion Criteria:

  1. Age 11 - 17 years
  2. Male and Female subjects
  3. BMI >= 95th percentile according to CDC body mass index chart for age and gender
  4. Must be willing to participate and undergo "willingness to change" evaluation
  5. Metabolic Syndrome(MetS) which is defined when 3 of the following are met:
  6. Central adiposity (waist circumference ≥90th% for age and sex)
  7. Hypertriglyceridemia (triglycerides ≥ 110mg/dl)
  8. Low HDL cholesterol ≤40mg/dl
  9. Elevated blood pressure systolic or diastolic blood pressure > 90th % adjusted for age, sex and height or ≥ 130/85
  10. IFG (Impaired fasting glucose ≥ 100mg/dl or elevated HOMA- IR ≥3.16)
  11. ALT greater than 60 U/L and Non Alcoholic Fatty Liver Disease based on histologic confirmation on liver biopsy (minimum of 5% of hepatocytes with macrovesicular fat) obtained within 6 months before randomization

Exclusion Criteria:

  1. Those patients with a history of poor compliance or adherence to energy restriction diets
  2. Patients on medications that could alter appetite including glucocorticoids, psychostimulants (Vyvanse, Adderall), psychotropic medications (Zoloft, Risperdal), and antihyperglycemic medications (metformin, sulfonylurea)
  3. Patients with the following illnesses:
  4. Type 2 diabetes
  5. Renal disease
  6. Mental diseases (mood, psychotic and anxiety disorders)
  7. Developmental delay
  8. Autism and autism spectrum disorders
  9. Any liver disease except for non alcoholic fatty liver (NAFLD)
  10. Metabolic disorders (tyrosinemia, glycogen storage disease, lysosomal disorders)
  11. Congenital heart disease
  12. Myopathies or muscular disorders/disability
  13. Patients who follow a (cultural or religious) vegetarian lifestyle as this would not be compatible with Carbohydrate Restriction (need for high quality protein)
  14. Prepubertal patients defined by a tanner stage of 1
  15. Current or history of significant alcohol consumption

Concise Summary of Project:

This is a 6-month prospective, randomized control trial enrolling patients referred to the Children's Medical Center COACH Program. The COACH Program is a medical weight management clinic, which serves obese children in order to diagnose and treat associated co-morbid conditions.

Subjects meeting all enrollment criteria will be randomized to either a carbohydrate- or calorie-restricted diet. They will be committed to this fixed meal plan for 6 months and dietary education by a certified dietician will be provided. This will include the allowed caloric intake and content, which is calculated by a bioelectric impedance meter (GE In Body 520) specific to patient's age, gender, and weight.

The carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat. The calorie-restricted diet is composed of 50%carbohydrate, 15-20% protein and 30-35% fat. Patients will be seen by a psychologist to help with goal setting, self-monitoring and problem solving. Dietary compliance will be followed regularly by weekly phone calls for the first 3 months and then monthly afterwards by the research personnel. A 72-hour dietary recall will be conducted by our dietician every other month. Subjects will be followed in the COACH clinic monthly. A detailed schedule will be outlined and provided to the families at each visit. Any missed appointments will be rescheduled within 3 to 7 days, and the families will be contacted immediately to offer assistance for the next visit. During this study, subjects will be monitored with urine tests and blood tests to ensure safety while undergoing the prescribed diet.

The first proton hepatic magnetic spectroscopy (H-MRS) will be done prior to initiating the dietary intervention. A second H-MRS will be obtained after 2 months (at visit 3) on the assigned dietary therapy. The final H-MRS will be performed after completion of the 6 month dietary intervention. At the 6 month completion, the subjects will be seen in clinic and blood work with urine testing will be done. Their final visit will be 4 to 6 months post dietary intervention to assess weight maintenance.

Being tested
Diet Intervention
Keywords
NAFLD, Metabolic syndrome, Hepatic Magnetic Resonance Spectroscopy, Obesity
Medical subject headings
Non-alcoholic Fatty Liver Disease, Fatty Liver, Obesity, Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Diet InterventionOther

Study groups in NCT02358928
Study groupRoleWhat they receive
Low calorie dietOtherCalorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
Receives: Other: Diet Intervention
Low carbohydrate dietOtherCarbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
Receives: Other: Diet Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HepaticTrigylceride Content quantified on proton magnetic spectroscopy (H-MRS)

    To compare the impact of dietary weight loss via carbohydrate-restriction and calorie-restriction on hepatic TG content quantified by H-MRS in obese children with biopsy-proven NAFLD and Met-S.

    Measured: 1 year

Secondary outcomes (3)
  1. BMI Z-score

    To compare BMI z-score in obese patients with NAFLD and Met-S after a 6 month dietary weight loss via either carbohydrate or calorie restriction.

    Measured: 1 year

  2. Cytokeratin-18

    Quantify the effect of dietary weight loss via carbohydrate- and calorie-restriction on serum markers of hepatic fibrosis.

    Measured: 1 year

  3. ALT (alanine transaminase)

    To compare ALT in obese patients with NAFLD and Met-S after a 6 month dietary weight loss via either carbohydrate or calorie restriction.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2015 (estimated)
  2. Study startJul 2014
  3. Primary completion18 Aug 2016
  4. Study completion18 Aug 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02358928
Sponsor's protocol ID
STU 082013 020
Acronym
NAFLD
Status last verified
Jan 2022
First submitted
29 Jan 2015
Last updated
28 Jan 2022
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Diet Intervention in people with NAFLD and Fatty Liver, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HepaticTrigylceride Content quantified on proton magnetic spectroscopy (H-MRS) (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in